University of Wisconsin–Madison

Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease

This project was led by: Cynthia Carlsson MD

This project was funded by: NIH and Eli Lilly

The term of this project was: May 2014 to June 2019

The number of subjects scanned during this project was: 30

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4
study” for short) is a clinical study for older individuals (65 to 85 years of age) who may be at risk for memory loss due to Alzheimer’s disease (AD).
The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as “amyloid” or “beta amyloid” plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss.
The A4 anti-amyloid investigational drug targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD.